Wei Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wei Sun has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Hongmei Yu
China-Japan Union Hospital, Jilin University
7 shared publicationsYawei Gou
6 shared publicationsMingming Zhang
5 shared publicationsRuonan Wang
4 shared publicationsJiayi Tian
Center for Reproductive Medicine and Center for Prenatal Diagnosis
3 shared publicationsLingling Liu
3 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1911347
20(S)-protopanaxadiol enhances temozolomide responsiveness in MGMT-expressing glioblastoma: Wnt/β-catenin attenuation and MGMT downregulation
Background: Glioblastoma is a highly aggressive primary brain malignancy, and O 6 -methylguanine-DNA methyltransferase (MGMT)-mediated DNA repair contributes to reduced temozolomide (TMZ) responsiveness. This study investigated whether 20(S)-protopanaxadiol (20(S)-PPD) enhances TMZ responsiveness in MGMT-expressing glioblastoma models and explored a potential mechanism. Methods: U87, U251, LN18, and T98G glioblastoma cells were studied, with combination and mechanistic analyses focused on MGMT-expressing LN18 and T98G cells. Network pharmacology was used to prioritize candidate targets and pathways, followed by experimental evaluation using cell viability, apoptosis, migration, invasion, comet assays, western blotting, and immunofluorescence assays. Preclinical in vivo activity was assessed in an intracranial zebrafish xenograft model and an LN18 subcutaneous xenograft model in BALB/c nude mice. Results: 20(S)-PPD reduced viability in all four cell lines and promoted apoptosis while decreasing migration- and invasion-related phenotypes in LN18 and T98G cells. Combined treatment produced greater inhibitory effects than either monotherapy and enhanced TMZ-induced DNA damage. Network pharmacology prioritized Wnt signaling as a candidate pathway. Subsequent cellular and in vivo analyses showed attenuated Wnt/β-catenin signaling and reduced MGMT expression after 20(S)-PPD treatment. β-Catenin or MGMT overexpression partially attenuated the TMZ-sensitizing effect of 20(S)-PPD. The combination treatment markedly inhibited tumor growth in both xenograft models. Conclusion: 20(S)-PPD enhanced TMZ responsiveness in MGMT-expressing glioblastoma models, and this effect was associated with attenuated Wnt/β-catenin signaling and reduced MGMT expression. Acquired TMZ-resistant derivatives and patient-derived resistant models were not examined; therefore, the conclusions are limited to the models evaluated here. These findings provide preclinical evidence supporting further evaluation of 20(S)-PPD as a potential TMZ chemosensitizer.
- 17 August 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1911347
Open Access20(S)-protopanaxadiol enhances temozolomide responsiveness in MGMT-expressing glioblastoma: Wnt/β-catenin attenuation and MGMT downregulation
Background: Glioblastoma is a highly aggressive primary brain malignancy, and O 6 -methylguanine-DNA methyltransferase (MGMT)-mediated DNA repair contributes to reduced temozolomide (TMZ) responsiveness. This study investigated whether 20(S)-protopanaxadiol (20(S)-PPD) enhances TMZ responsiveness in MGMT-expressing glioblastoma models and explored a potential mechanism. Methods: U87, U251, LN18, and T98G glioblastoma cells were studied, with combination and mechanistic analyses focused on MGMT-expressing LN18 and T98G cells. Network pharmacology was used to prioritize candidate targets and pathways, followed by experimental evaluation using cell viability, apoptosis, migration, invasion, comet assays, western blotting, and immunofluorescence assays. Preclinical in vivo activity was assessed in an intracranial zebrafish xenograft model and an LN18 subcutaneous xenograft model in BALB/c nude mice. Results: 20(S)-PPD reduced viability in all four cell lines and promoted apoptosis while decreasing migration- and invasion-related phenotypes in LN18 and T98G cells. Combined treatment produced greater inhibitory effects than either monotherapy and enhanced TMZ-induced DNA damage. Network pharmacology prioritized Wnt signaling as a candidate pathway. Subsequent cellular and in vivo analyses showed attenuated Wnt/β-catenin signaling and reduced MGMT expression after 20(S)-PPD treatment. β-Catenin or MGMT overexpression partially attenuated the TMZ-sensitizing effect of 20(S)-PPD. The combination treatment markedly inhibited tumor growth in both xenograft models. Conclusion: 20(S)-PPD enhanced TMZ responsiveness in MGMT-expressing glioblastoma models, and this effect was associated with attenuated Wnt/β-catenin signaling and reduced MGMT expression. Acquired TMZ-resistant derivatives and patient-derived resistant models were not examined; therefore, the conclusions are limited to the models evaluated here. These findings provide preclinical evidence supporting further evaluation of 20(S)-PPD as a potential TMZ chemosensitizer.
- Open Access
Trained Immunity in Neutrophils and Mononuclear Phagocytes: Mechanisms and Pathophysiological Functions
Trained immunity refers to the enduring functional reprogramming of innate immune cells after particular stimuli, driven by epigenetic and metabolic alterations that augment non-specific responses upon subsequent exposure. Neutrophils and monocytes/macrophages, as essential innate effectors, are crucial for the induction and control of trained immunity, which is the primary emphasis of this review. Neutrophils, the predominant circulating leukocytes, were historically considered incapable of memory owing to their brief lifespan. Emerging evidence indicates that trained immunity functions at the bone marrow progenitor level, influencing granulopoiesis to produce neutrophils with lasting functional modifications. This research offers new insights into neutrophil functions in infection, cancer, and inflammation. Monocytes and macrophages, characterized by phenotypic plasticity and tissue residence, function as conventional models of trained immunity. They experience direct peripheral reprogramming or emerge as primed descendants of trained bone marrow precursors, performing pro-inflammatory or reparative roles in malignancies, infections, and ischemia lesions. This study comprehensively outlines the regulatory mechanisms of trained immunity in these cells, clarifies their functions in various clinical situations, and examines therapeutic applications. Comprehending these pathways is crucial for elucidating the cellular foundation of innate immunological memory, uncovering its multiple functions in disease, and guiding innovative therapeutics aimed at granulopoiesis and monocyte-macrophage polarization.
Open AccessTrained Immunity in Neutrophils and Mononuclear Phagocytes: Mechanisms and Pathophysiological Functions
Trained immunity refers to the enduring functional reprogramming of innate immune cells after particular stimuli, driven by epigenetic and metabolic alterations that augment non-specific responses upon subsequent exposure. Neutrophils and monocytes/macrophages, as essential innate effectors, are crucial for the induction and control of trained immunity, which is the primary emphasis of this review. Neutrophils, the predominant circulating leukocytes, were historically considered incapable of memory owing to their brief lifespan. Emerging evidence indicates that trained immunity functions at the bone marrow progenitor level, influencing granulopoiesis to produce neutrophils with lasting functional modifications. This research offers new insights into neutrophil functions in infection, cancer, and inflammation. Monocytes and macrophages, characterized by phenotypic plasticity and tissue residence, function as conventional models of trained immunity. They experience direct peripheral reprogramming or emerge as primed descendants of trained bone marrow precursors, performing pro-inflammatory or reparative roles in malignancies, infections, and ischemia lesions. This study comprehensively outlines the regulatory mechanisms of trained immunity in these cells, clarifies their functions in various clinical situations, and examines therapeutic applications. Comprehending these pathways is crucial for elucidating the cellular foundation of innate immunological memory, uncovering its multiple functions in disease, and guiding innovative therapeutics aimed at granulopoiesis and monocyte-macrophage polarization.
- Open Access
- 5 April 2026
- Published by Elsevier in Drug Resistance Updates
- Vol. 87, 101393
Interferon regulatory factor 5 associated neutrophil reprogramming by trained immunity protects against lethal-dose bacterial sepsis
- 5 April 2026
- Published by Elsevier in Drug Resistance Updates
- Vol. 87, 101393
Open AccessInterferon regulatory factor 5 associated neutrophil reprogramming by trained immunity protects against lethal-dose bacterial sepsis
- Open Access
- 30 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1731995
Immunometabolic reprogramming in sepsis: mechanisms, clinical endotypes, and therapeutic opportunities
Sepsis, a systemic inflammatory syndrome triggered by infection, is tightly linked to dysregulated host immunometabolism. We review three hallmark metabolic alterations. First, a shift from oxidative phosphorylation (OXPHOS) to glycolysis provides rapid ATP early on; prolonged glycolytic engagement, however, drives excessive cytokine release through abnormal accumulation of metabolic intermediates. Second, impaired fatty acid oxidation (FAO) and disrupted cholesterol homeostasis not only compromise energy supply but also amplify pro-inflammatory signaling. Third, mitochondrial dysfunction unleashes reactive oxygen species (ROS) and derails metabolic homeostasis, promoting multi-organ injury. Notably, short-chain fatty acids (SCFAs) derived from the gut microbiota fine tune pro-versus anti-inflammatory responses via epigenetic regulation of immune cells. We further discuss how metabolic reprogramming governs macrophage polarization and T cell exhaustion, and we summarize therapeutic strategies that target key metabolic nodes. This review provides an integrated perspective on the immunometabolic mechanisms of sepsis and offers a rationale for metabolism-based precision interventions.
- 30 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1731995
Open AccessImmunometabolic reprogramming in sepsis: mechanisms, clinical endotypes, and therapeutic opportunities
Sepsis, a systemic inflammatory syndrome triggered by infection, is tightly linked to dysregulated host immunometabolism. We review three hallmark metabolic alterations. First, a shift from oxidative phosphorylation (OXPHOS) to glycolysis provides rapid ATP early on; prolonged glycolytic engagement, however, drives excessive cytokine release through abnormal accumulation of metabolic intermediates. Second, impaired fatty acid oxidation (FAO) and disrupted cholesterol homeostasis not only compromise energy supply but also amplify pro-inflammatory signaling. Third, mitochondrial dysfunction unleashes reactive oxygen species (ROS) and derails metabolic homeostasis, promoting multi-organ injury. Notably, short-chain fatty acids (SCFAs) derived from the gut microbiota fine tune pro-versus anti-inflammatory responses via epigenetic regulation of immune cells. We further discuss how metabolic reprogramming governs macrophage polarization and T cell exhaustion, and we summarize therapeutic strategies that target key metabolic nodes. This review provides an integrated perspective on the immunometabolic mechanisms of sepsis and offers a rationale for metabolism-based precision interventions.
- Open Access
- 12 December 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (2) , 1022-1045
Multifunctional extracellular vesicles inhibiting autophagy ameliorate immunotherapy in non-small cell lung cancer
- 12 December 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (2) , 1022-1045
Open AccessMultifunctional extracellular vesicles inhibiting autophagy ameliorate immunotherapy in non-small cell lung cancer
- Top Cited PapersOpen Access
- 25 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (5) , 1965
Neutrophils: Linking Inflammation to Thrombosis and Unlocking New Treatment Horizons
Neutrophils play a key role in inflammatory responses and thrombosis, but their complex interactions in disease pathogenesis are not fully understood. This review examines the multifaceted roles of neutrophils, focusing on their activation, cytokine release, and formation of neutrophil extracellular traps (NETs), which contribute to host defense and thrombosis. We discuss the interaction between inflammation and coagulation, the direct effect of neutrophils on thrombus stability, and their involvement in pathological thrombotic diseases. The therapeutic potential of neutrophil drug loading in the treatment of thrombosis, as well as the clinical implications and future research directions, are highlighted. The aim of this review is to gain insight into the critical neutrophil–inflammation–thrombus axis and its potential as a therapeutic target for thrombotic diseases and to suggest possible directions for neutrophil-loaded drug therapy for thrombosis.
- 25 February 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (5) , 1965
Top Cited PapersOpen AccessNeutrophils: Linking Inflammation to Thrombosis and Unlocking New Treatment Horizons
Neutrophils play a key role in inflammatory responses and thrombosis, but their complex interactions in disease pathogenesis are not fully understood. This review examines the multifaceted roles of neutrophils, focusing on their activation, cytokine release, and formation of neutrophil extracellular traps (NETs), which contribute to host defense and thrombosis. We discuss the interaction between inflammation and coagulation, the direct effect of neutrophils on thrombus stability, and their involvement in pathological thrombotic diseases. The therapeutic potential of neutrophil drug loading in the treatment of thrombosis, as well as the clinical implications and future research directions, are highlighted. The aim of this review is to gain insight into the critical neutrophil–inflammation–thrombus axis and its potential as a therapeutic target for thrombotic diseases and to suggest possible directions for neutrophil-loaded drug therapy for thrombosis.
- Open Access
The role of neutrophil typing in homeostatic resilience protective model of inflammatory preconditioning
Sepsis is a systemic inflammatory response syndrome (SIRS) characterized by a dysregulated host response to infection that results in organ dysfunction. The response of neutrophils to early inflammation is critical, interferon regulatory factors 4 (IRF4) and interferon regulatory factors 5 (IRF5) are expressed in most cell types of the immune system, but the relationship between the role of IRF4 and IRF5 in preconditioning-protected septic peritonitis mouse model and neutrophils response remains unknown. In this study, we used an E.coli -induced septic peritonitis mouse model and zebrafish model to explore the relationship between neutrophil inflammation and IRF subtype changes in the process of septic peritonitis. Mechanistically, we found that the protein complex formed by polymorphonuclear neutrophils (PMN) and IRF5/MyD88 can secrete pro-inflammatory factors and directly kill invading bacteria. Author Summary: Numerous animal and clinical sepsis studies have shown that markedly impaired recruitment of neutrophils to sites of infection and failure to clear bacteria contribute to excessive inflammation and increased mortality in sepsis. In our previous work, we established an Escherichia coli ( E.coli ) lethal septic peritonitis model and a preconditioning-protected septic peritonitis mouse model. In the early stage of septic peritonitis, a large number of PMN infiltrate the peritoneal cavity, which produces an inflammatory response to invasive bacteria. In this study, the switching process between pro-inflammatory and anti-inflammatory attracted our attention. Our research shows that IRF5-IRF4 regulatory axis leads to a PMN phenotype switch in sepsis and the expression of IRF5 and IRF4 was related to PMN pro-inflammatory (N1 type) and anti-inflammatory (N2 type) phenotypes, respectively.
Open AccessThe role of neutrophil typing in homeostatic resilience protective model of inflammatory preconditioning
Sepsis is a systemic inflammatory response syndrome (SIRS) characterized by a dysregulated host response to infection that results in organ dysfunction. The response of neutrophils to early inflammation is critical, interferon regulatory factors 4 (IRF4) and interferon regulatory factors 5 (IRF5) are expressed in most cell types of the immune system, but the relationship between the role of IRF4 and IRF5 in preconditioning-protected septic peritonitis mouse model and neutrophils response remains unknown. In this study, we used an E.coli -induced septic peritonitis mouse model and zebrafish model to explore the relationship between neutrophil inflammation and IRF subtype changes in the process of septic peritonitis. Mechanistically, we found that the protein complex formed by polymorphonuclear neutrophils (PMN) and IRF5/MyD88 can secrete pro-inflammatory factors and directly kill invading bacteria. Author Summary: Numerous animal and clinical sepsis studies have shown that markedly impaired recruitment of neutrophils to sites of infection and failure to clear bacteria contribute to excessive inflammation and increased mortality in sepsis. In our previous work, we established an Escherichia coli ( E.coli ) lethal septic peritonitis model and a preconditioning-protected septic peritonitis mouse model. In the early stage of septic peritonitis, a large number of PMN infiltrate the peritoneal cavity, which produces an inflammatory response to invasive bacteria. In this study, the switching process between pro-inflammatory and anti-inflammatory attracted our attention. Our research shows that IRF5-IRF4 regulatory axis leads to a PMN phenotype switch in sepsis and the expression of IRF5 and IRF4 was related to PMN pro-inflammatory (N1 type) and anti-inflammatory (N2 type) phenotypes, respectively.
- Open Access
- 24 January 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1032355
Potential targeted therapy based on deep insight into the relationship between the pulmonary microbiota and immune regulation in lung fibrosis
Pulmonary fibrosis is an irreversible disease, and its mechanism is unclear. The lung is a vital organ connecting the respiratory tract and the outside world. The changes in lung microbiota affect the progress of lung fibrosis. The latest research showed that lung microbiota differs in healthy people, including idiopathic pulmonary fibrosis (IPF) and acute exacerbation-idiopathic pulmonary fibrosis (AE-IPF). How to regulate the lung microbiota and whether the potential regulatory mechanism can become a necessary targeted treatment of IPF are unclear. Some studies showed that immune response and lung microbiota balance and maintain lung homeostasis. However, unbalanced lung homeostasis stimulates the immune response. The subsequent biological effects are closely related to lung fibrosis. Core fucosylation (CF), a significant protein functional modification, affects the lung microbiota. CF regulates immune protein modifications by regulating key inflammatory factors and signaling pathways generated after immune response. The treatment of immune regulation, such as antibiotic treatment, vitamin D supplementation, and exosome micro-RNAs, has achieved an initial effect in clearing the inflammatory storm induced by an immune response. Based on the above, the highlight of this review is clarifying the relationship between pulmonary microbiota and immune regulation and identifying the correlation between the two, the impact on pulmonary fibrosis, and potential therapeutic targets.
- 24 January 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1032355
Open AccessPotential targeted therapy based on deep insight into the relationship between the pulmonary microbiota and immune regulation in lung fibrosis
Pulmonary fibrosis is an irreversible disease, and its mechanism is unclear. The lung is a vital organ connecting the respiratory tract and the outside world. The changes in lung microbiota affect the progress of lung fibrosis. The latest research showed that lung microbiota differs in healthy people, including idiopathic pulmonary fibrosis (IPF) and acute exacerbation-idiopathic pulmonary fibrosis (AE-IPF). How to regulate the lung microbiota and whether the potential regulatory mechanism can become a necessary targeted treatment of IPF are unclear. Some studies showed that immune response and lung microbiota balance and maintain lung homeostasis. However, unbalanced lung homeostasis stimulates the immune response. The subsequent biological effects are closely related to lung fibrosis. Core fucosylation (CF), a significant protein functional modification, affects the lung microbiota. CF regulates immune protein modifications by regulating key inflammatory factors and signaling pathways generated after immune response. The treatment of immune regulation, such as antibiotic treatment, vitamin D supplementation, and exosome micro-RNAs, has achieved an initial effect in clearing the inflammatory storm induced by an immune response. Based on the above, the highlight of this review is clarifying the relationship between pulmonary microbiota and immune regulation and identifying the correlation between the two, the impact on pulmonary fibrosis, and potential therapeutic targets.
- Open Access
- 14 September 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1008080
Peripheral and intestinal mucosal-associated invariant T cells in premature infants with necrotizing enterocolitis
Background: Necrotizing enterocolitis (NEC) is a potentially fatal inflammatory gastrointestinal disease in preterm infants with unknown pathogenesis. Mucosal-associated invariant T (MAIT) cells primarily accumulate at sites where exposure to microbes is ubiquitous and regulate immunological responses. As the implications of these cells in NEC development in premature infants remain unknown, we investigated the role and characteristics of MAIT cells in NEC pathogenesis.Methods: The percentage of different MAIT cell subsets in peripheral blood samples of 30 preterm infants with NEC and 22 control subjects was estimated using flow cytometry. The frequency of MAIT cells in the intestinal tissues of five NEC patients and five control subjects was also examined. The level of serum cytokines was estimated using cytometric bead array. Potential associations between the different measurements were analyzed using the Spearman’s correlation test.Results: Compared with controls, the NEC patients were found to have significantly reduced percentages of circulating CD161+ CD3+ CD8αα+ T cells and CD161+ CD3+ TCRγδ-TCRVa7.2+ MAIT cells. In the intestinal tissues, the percentage of MAIT cells was significantly higher in samples from the NEC patients than the controls. Furthermore, the percentage of circulating MAIT cells in the peripheral blood samples was inversely correlated with that in the intestinal tissues of the NEC patients. The percentage of CD8αα+ MAIT cells was found to be significantly reduced in both peripheral blood and intestinal tissues of NEC patients. Following treatment, the frequency of circulating MAIT cells significantly increased in NEC patients and reached a level similar to that in the control subjects. However, there was no difference in the percentage of circulating CD8αα+ MAIT cells before and after treatment in the NEC patients.Conclusion: Our results suggested that during the development of NEC MAIT cells accumulate in the inflammatory intestinal tissues, while the percentage of CD8aa+ MAIT cells is significantly decreased, which may lead to the dysfunction of MAIT cells in gut immunity.
- 14 September 2022
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 13, 1008080
Open AccessPeripheral and intestinal mucosal-associated invariant T cells in premature infants with necrotizing enterocolitis
Background: Necrotizing enterocolitis (NEC) is a potentially fatal inflammatory gastrointestinal disease in preterm infants with unknown pathogenesis. Mucosal-associated invariant T (MAIT) cells primarily accumulate at sites where exposure to microbes is ubiquitous and regulate immunological responses. As the implications of these cells in NEC development in premature infants remain unknown, we investigated the role and characteristics of MAIT cells in NEC pathogenesis.Methods: The percentage of different MAIT cell subsets in peripheral blood samples of 30 preterm infants with NEC and 22 control subjects was estimated using flow cytometry. The frequency of MAIT cells in the intestinal tissues of five NEC patients and five control subjects was also examined. The level of serum cytokines was estimated using cytometric bead array. Potential associations between the different measurements were analyzed using the Spearman’s correlation test.Results: Compared with controls, the NEC patients were found to have significantly reduced percentages of circulating CD161+ CD3+ CD8αα+ T cells and CD161+ CD3+ TCRγδ-TCRVa7.2+ MAIT cells. In the intestinal tissues, the percentage of MAIT cells was significantly higher in samples from the NEC patients than the controls. Furthermore, the percentage of circulating MAIT cells in the peripheral blood samples was inversely correlated with that in the intestinal tissues of the NEC patients. The percentage of CD8αα+ MAIT cells was found to be significantly reduced in both peripheral blood and intestinal tissues of NEC patients. Following treatment, the frequency of circulating MAIT cells significantly increased in NEC patients and reached a level similar to that in the control subjects. However, there was no difference in the percentage of circulating CD8αα+ MAIT cells before and after treatment in the NEC patients.Conclusion: Our results suggested that during the development of NEC MAIT cells accumulate in the inflammatory intestinal tissues, while the percentage of CD8aa+ MAIT cells is significantly decreased, which may lead to the dysfunction of MAIT cells in gut immunity.
- Open Access
- 1 July 2020
- Published by SAGE Publications in Dose-Response
- Vol. 18 (3)
Protective Effect of Metformin on Sepsis Myocarditis in Zebrafish
We found in previous study that metformin could treat sepsis myocarditis in a mouse model. We employed the zebrafish model organism to investigate the effect of metformin on sepsis myocarditis. Wild-type zebrafish was used to establish a sepsis myocarditis model and combined with image software analysis and cytokine detection, the protective dose of metformin was determined. The results showed that immersion with Escherichia coli could cause 75% mortality in zebrafish and make larvae appear as characteristics of severe sepsis myocarditis. Pretreatment with 10 mM metformin for 3 hours could effectively reduce heart congestion and swelling in zebrafish with sepsis myocarditis and increased the heart rate. It could reduce the mortality and prolong the survival time of zebrafish with sepsis myocarditis; Tg(mpx: EGFP) transgenic zebrafish were adopted to explore the number of neutrophils in zebrafish heart before and after metformin protection, and metformin could maintain the number of neutrophils in zebrafish heart; quantitative real-time reverse transcription–polymerase chain reaction showed that metformin could reduce the expression of pro-inflammatory factors, tumor necrosis factor-α and interleukin (IL)-6, and could promote the anti-inflammatory factor, transforming growth factor-β and IL-10 expression. We established a zebrafish sepsis myocarditis model and applied metformin in advance to provide a protective effect on the zebrafish heart.
- 1 July 2020
- Published by SAGE Publications in Dose-Response
- Vol. 18 (3)
Open AccessProtective Effect of Metformin on Sepsis Myocarditis in Zebrafish
We found in previous study that metformin could treat sepsis myocarditis in a mouse model. We employed the zebrafish model organism to investigate the effect of metformin on sepsis myocarditis. Wild-type zebrafish was used to establish a sepsis myocarditis model and combined with image software analysis and cytokine detection, the protective dose of metformin was determined. The results showed that immersion with Escherichia coli could cause 75% mortality in zebrafish and make larvae appear as characteristics of severe sepsis myocarditis. Pretreatment with 10 mM metformin for 3 hours could effectively reduce heart congestion and swelling in zebrafish with sepsis myocarditis and increased the heart rate. It could reduce the mortality and prolong the survival time of zebrafish with sepsis myocarditis; Tg(mpx: EGFP) transgenic zebrafish were adopted to explore the number of neutrophils in zebrafish heart before and after metformin protection, and metformin could maintain the number of neutrophils in zebrafish heart; quantitative real-time reverse transcription–polymerase chain reaction showed that metformin could reduce the expression of pro-inflammatory factors, tumor necrosis factor-α and interleukin (IL)-6, and could promote the anti-inflammatory factor, transforming growth factor-β and IL-10 expression. We established a zebrafish sepsis myocarditis model and applied metformin in advance to provide a protective effect on the zebrafish heart.